Over 70-85% of men with advanced prostate cancer (PCa) develop bone metastases characterized by severe bone pain and increased likelihood of bone fracture. This results in decreased quality of life and acts a predictor of higher mortality. Mechanistically, it is hypothesized that skeletal pathologies such as osteolytic lesions and abnormal osteoblastic activity drive these symptoms. The role of immune cells in bone cancer pain remains understudied. Here we generated a novel bone metastasis model in immunocompetent C57BL/6 and immunodeficient Rag2-/-mice to investigate the contribution of immune cells in the development of bone pain.
INTRODUCTION AND OBJECTIVES:
Over 70-85% of men with advanced prostate cancer (PCa) develop bone metastases characterized by severe bone pain and increased likelihood of bone fracture. This results in decreased quality of life and acts a predictor of higher mortality. Mechanistically, it is hypothesized that skeletal pathologies such as osteolytic lesions and abnormal osteoblastic activity drive these symptoms. The role of immune cells in bone cancer pain remains understudied. Here we generated a novel bone metastasis model in immunocompetent C57BL/6 and immunodeficient Rag2-/-mice to investigate the contribution of immune cells in the development of bone pain.
METHODS: A murine prostate cancer bone metastasis pain model was established by intra-femural transplantation and engraftment of a HiMyC mouse prostate cancer cell line (B6CaP). Behavioral assays were used to measure the impact of tumor growth on pain development, gait, depression and anxiety. Mechanical allodynia was tested using Von Frey fiber testing at 5-7 days intervals. At 2 months post-injection tissues, including femurs, dorsal root ganglion and spinal cord were collected for histology and immunohistochemistry.
RESULTS: 3-weeks post-injection, C57BL/6 mice with prostate cancer engrafted to their right femur showed statistically lower threshold for paw withdrawal responses (to mechanical stimulation) compared to controls. At 8 weeks, the Zero maze and Digi-gait tests indicated reduced and aberrant movement capacity associated with emotional activity in engrafted mice compared with controls. Increased CGRP and neuronal p75NTR expression was observed in both the superficial dorsal horn and afferent neurons in dorsal root ganglion (DRG) in tumor-bearing mice. In the immunodeficient Rag2-/-animals however, we observed blunted responses to paw withdrawal testing despite tumor engraftment. This reduced pain development was associated with dramatically attenuated expression of CGRP, NGF and its receptors compared to C57BL/6 engrafted counterparts. Furthermore, we demonstrate that GABA neuron-associated inhibitory synapses are increased in the superficial dorsal horn in engrafted Rag2-/-mice which, was less observed in C57BL/6 animals.
CONCLUSIONS: These data suggest a significant contribution of the immune system to bone pain associated with metastatic bone cancer. Thus, immune cell interaction with nociceptive pathway may be the targets for the development of novel analgesic strategy. 177 Lu-PSMA-617) therapy is increasingly used in patients with advanced metastatic castrationresistant prostate cancer. However, limitations are a low PSMA surface expression in certain patients. We have previously shown that high doses of dutasteride, a 5-alpha-reductase inhibitor generally used for the treatment of benign prostatic enlargement, alter the PSMA expression in vitro. Using dutasteride in patients might increase the response to therapy via upregulation of PSMA expression. Therefore, we further analyzed the dose and time dependent effects of dutasteride in vitro.
METHODS: Androgen receptor expressing prostate cancer cells (LNCaP) were treated for 7 to 14 days with vehicle control (0.1% DMSO) or different concentrations of dutasteride (0.25mM, 0.5mM, 1mM, 5mM). PSMA surface expression was assessed using flow cytometry (FACS) and immunocytochemistry. Total PSMA expression was analyzed by immunoblotting (WES). In addition, uptake and internalization assays of 177 Lu-PSMA-617 were performed. RESULTS: Dutasteride treatment resulted in a significant upregulation of PSMA surface expression compared to vehicle control (0.1% DMSO) after 7 days in all tested concentrations (0.25mM: 155%, 0.5mM: 168%, 1mM: 218%, 5mM: 213%: all p <0.0001). After 14 days a further, dose dependent increase of PSMA surface expression was detectable (0.25mM: 156%: p <0.05, 0.5mM: 202%, 1mM: 317%, 5mM: 461%: all p <0.0001). Total PSMA protein expression was significantly increased after treatment of cells with high concentrations of dutasteride using 5mM for 7 (330%: p <0.05) or 14 days (330%: p <0.05), whereas lower concentration did not alter total PSMA expression compared to vehicle control. Further analysis revealed a dose dependent increase in uptake and internalization of 177 Lu-PSMA-617 after 7 and 14 days. However, a significantly increased uptake was only observed using 5mM (7d: 161%, 14d: 151: all p <0.05) and 1mM after 14 days (146%: p <0.05).
CONCLUSIONS: Our results show a concentration dependent effect of dutasteride on PSMA expression and uptake of 
MP68-04 ACTIVATABLE PHOTODYNAMIC THERAPY FOR PROSTATE CANCER BY NIR DYE/PHOTOSENSITIZER LOADED ALBUMIN NANOPARTICLES
Changwei Ji*, nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Prostate cancer is one of the leading causes of death in men worldwide. Photodynamic therapy (PDT) is a new emerging and promising strategy for the treatment of prostate cancer. PDT uses a combination of light and a photosensitizer (PS) to kill cancer cells. However, most photosensitizers (PS) accumulate in normal tissues, in particular the skin and eyes, and can be activated by sunlight, causing severe side effects such as prolonged skin photosensitivity that have limited the clinical application of PDT. Herein, a novel strategy is presented to overcome these limitations using Indocyanine green (ICG) as an activatable PDT agent.
METHODS: ICG and Ce6 were encapsulated into HSA to form HSA-ICG-Ce6 NPs using a desolvation cross-linking technique. Particle size of nanoparticles were measured by dynamic light scattering (DLS) and Transmission Electron Microscope (TEM). Quench of Ce6 fluorescence and recovery of Ce6 photosensitivity under NIR irradiation were tested. The combination of activatable PDT and PTT effects for prostate cancer cells were evaluated. In vivo NIR imaging of HSA-ICG-Ce6 NPs and therapeutic efficacy of HSA-ICG-Ce6 NPs in prostate cancer model were perfoemd.
RESULTS: The average hydrodynamic diameter of NPs was 120.5 nm according to the results obtained from DLS. TEM imaging showed that HSA-ICG-Ce6 NPs is a spherical shape and is w120 nm in diameter. In vitro and vivo study showed that ICG effectively turned "OFF'' the phototoxicity of Ce6, and the degradation of ICG by laser irradiation at 808 nm could turn "ON'' the phototoxicity of Ce6. In addition, ICG could produce heat upon NIR irradiation to kill cancer cells, which could be used as a photothermal therapy (PTT). Therapeutic efficacy of HSA-ICG-Ce6 NPs in prostate cancer model showed that tumors were completely damaged in the mice treated by combined PTT with activated PDT group. CONCLUSIONS: Our designed HSA nanoparticles containing ICG and Ce6 could be used as an activatable PDT combined with PTT for the treatment of prostate cancer.
